Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

26.26 +0.37 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors ↗
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors. 
Via Chartmill
News headline image
Peering Into Catalyst Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential ↗
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks. 
Via Chartmill
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Is Catalyst Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing This Quarter ↗
 
Via Benzinga
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A CANSLIM Candidate With Strong Growth Metrics ↗
CATALYST PHARMACEUTICALS (CPRX) meets key CANSLIM criteria with strong earnings growth, high profitability, and market-leading relative strength. A debt-free balance sheet adds appeal. 
Via Chartmill
News headline image
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors ↗
CATALYST PHARMACEUTICALS INC (CPRX) shows strong earnings growth, high profitability, and solid cash flow, making it a standout for growth investors. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and Value ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors ↗
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors ↗
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its... 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Quality Investors ↗
Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid... 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential ↗
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a bullish technical setup, making it a stock to watch in the biotech sector. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A High Growth Momentum Stock with Strong Technical Setup ↗
CATALYST PHARMACEUTICALS (CPRX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Candidate for Affordable Growth Investors ↗
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive option for investors seeking affordable growth stocks in biotech. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. ↗
A fundamental and technical analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is Poised for High Growth. 
Via Chartmill
News headline image
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors ↗
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A top pick for growth investors. 
Via Chartmill
News headline image
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? ↗
A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) showing high EPS and FCF growth while beating expectations 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Does CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) meet the Minervini criteria? ↗
A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
News headline image
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s quality characteristics. ↗
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Deserves Consideration as a Quality Investment. 
Via Chartmill
News headline image
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors ↗
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Based on fundamental and technical analysis of NASDAQ:CPRX we ask: Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
News headline image
Investors should take note of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a growth stock that remains attractively priced. ↗
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.